Adjuvant Nivolumab Therapy for Upper Tract Urothelial Carcinoma: A Single-Institution Study
This is one of the first real-world experiences focused exclusively on patients receiving adjuvant nivolumab for UTUC. The observed delay in distant progression may reflect the systemic therapeutic activity of immune checkpoint blockade in this setting.
Authors
- Naohiro Fujimoto (ORCID: https://orcid.org/0000-0002-5256-6415)
- Eiji Kashiwagi (ORCID: https://orcid.org/0000-0001-9424-3764)
- Yui Mizushima
- Ikko Tomisaki (ORCID: https://orcid.org/0000-0002-7818-0780)
- Akinori Minato (ORCID: https://orcid.org/0000-0001-6303-1128)
- Rieko Kimuro
- Yujiro Nagata
- Yoshihiro Sugita
- K. Jojima
- Katsuyoshi Higashijima
Institutions
- University of Occupational and Environmental Health Japan (JP)
- Kurosawa Hospital (JP)
Publication Details
- Journal
- Cureus
- Published
- 2025-08-12
- DOI
- https://doi.org/10.7759/cureus.89897
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Occupational and Environmental Health